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ABSTRACT
Objectives: Routine inﬂuenza vaccination is currently rec-
ommended in several countries for people aged more than 60
or 65 years or with high risk of complications. A lower age
threshold of 50 years has been recommended in the United
States since 1999. To help policymakers consider whether
such a policy should be adopted more widely, we conducted
an economic evaluation of lowering the age limit for routine
inﬂuenza vaccination to 50 years in Brazil, France, Germany,
and Italy.
Methods: The probabilistic model was designed to compare
in a single season the costs and clinical outcomes associated
with two alternative vaccination policies for persons aged 50
to 64 years: reimbursement only for people at high risk of
complications (current policy), and reimbursement for all
individuals in this age group (proposed policy). Two perspec-
tives were considered: third-party payer (TPP) and societal.
Model inputs were obtained primarily from the published lit-
erature and validated through expert opinion. The historical
distribution of annual inﬂuenza-like illness (ILI) incidence
was used to simulate the uncertain incidence in any given sea-
son. We estimated gains in unadjusted and quality-adjusted
life expectancy, and the cost per quality-adjusted life-year
(QALY) gained. Deterministic and probabilistic sensitivity
analyses were conducted.
Results: Comparing the proposed to the current policy, the
estimated mean costs per QALY gained were R$4,100,
€13,200, €31,400 and €15,700 for Brazil, France, Germany,
and Italy, respectively, from a TPP perspective. From the soci-
etal perspective, the age-based policy is predicted to yield net
cost savings in Germany and Italy, whereas the cost per
QALY decreased to R$2800 for Brazil and €8000 for France.
The results were particularly sensitive to the ILI incidence
rate, vaccine uptake, inﬂuenza fatality rate, and the costs of
administering vaccination. Assuming a cost-effectiveness
threshold ratio of €50,000 per QALY gained, the probabili-
ties of the new policy being cost-effective were 94% and
95% for France, 72% and near 100% for Germany, and
89% and 99% for Italy, from the TPP and societal perspec-
tives, respectively.
Conclusions: Extending routine inﬂuenza vaccination to
people more than 50 years of age is likely to be cost-effective
in all four countries studied.
Keywords: cost-effectiveness analysis, inﬂuenza, model, vac-
cination, vaccines.
Background and Objective
Inﬂuenza epidemics are associated with an increase in
acute respiratory infections, hospital admissions and
mortality [1–4], imposing a signiﬁcant burden of ill-
ness and placing an acute strain on health-care
resources. This has led to a widespread policy of pro-
viding routine annual vaccination for the elderly, who
are at high risk of potentially life-threatening com-
plications. In many countries (including France and
Italy), vaccination is recommended for people more
than 65 years old and for younger people with risk fac-
tors for inﬂuenza complications. In other countries,
such as Germany and Brazil, the policy is to vaccinate
all people aged more than 60 years, as well as younger
people at increased risk. The range of risk factors gov-
erning policy varies between countries, but generally
includes diabetes, chronic respiratory diseases (e.g.,
asthma, chronic obstructive pulmonary disease), car-
diovascular disease (e.g., ischemic heart disease, con-
gestive heart failure, stroke), immunodeﬁciencies (e.g.,
HIV), and cystic ﬁbrosis.
Implementing a risk-deﬁned vaccination policy
depends upon primary care providers taking concerted
action to identify and reach patients meeting the crite-
ria. As risk is a function of increasing age as well as
comorbidity [5], possibly a more practical means of
achieving coverage of at-risk patients would be simply
to lower the age threshold for routine eligibility.
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According to the US Advisory Committee on Immuni-
zation Practices (ACIP), “age-based strategies are more
successful in increasing vaccine coverage than patient-
selection strategies based on medical conditions” [6].
Taking this view in 1999, the American Academy of
Family Physicians lowered the recommended age
threshold for routine inﬂuenza vaccination from 65 to
50 years [5].
In publicly funded health-care systems, affordabil-
ity and value for money are inevitable factors in
planning  the  extent  of  provision  of  vaccination.
Cost-effectiveness analysis (CEA) provides a well-
established framework for determining whether target-
ing particular population subgroups represents good
value for money, as compared with alternative uses of
health-care resources. Inﬂuenza imposes costs not only
on health-care payers, but also on employers and
patients through lost productivity. Therefore, CEA
may take a broader, societal perspective in addition to
the more limited viewpoint of the health-care system.
Nichol has reviewed the cost-effectiveness evidence
for vaccination of three potential target groups: the
elderly, healthy younger adults, and children [7]. She
concluded that vaccination of the elderly provides
substantial economic beneﬁts; several US studies had
found that vaccination was cost-saving, whereas in a
range of other countries vaccination was always cost-
effective and in some cases cost-saving. Considering
healthy working adults, Nichol notes that although
this group is not at increased risk for serious compli-
cations, productivity losses are an important consider-
ation. When these were taken into account in
economic evaluations, two of three US trial-based
studies found that vaccination was cost-saving [8–10].
Unlike trials, model-based studies can accommodate
the annual variability of inﬂuenza incidence, so may
provide a more realistic picture of the possible range of
outcomes. Studies from Canada [11], the UK [12,13],
France [14], and Brazil [15] have found that vaccinat-
ing working adults is cost-saving when productivity
effects are included in the costing, whereas studies
from Finland [16] and Hong Kong concluded that it is
not [17]. A model developed by the US Ofﬁce of Tech-
nology Assessment found that vaccinating adults less
than 65 years of age would be highly cost-effective,
even without taking into account the impact of pro-
ductivity differences [18]. For countries considering
extending an age-based policy downward from a
threshold of 60 or 65 years, age stratiﬁcation may not
be important, as neither risk of inﬂuenza complica-
tions nor work participation rates are homogeneous
over the span of normal working age. A possible con-
servative approach to expansion might be ﬁrst to con-
sider a policy covering all adults aged more than
50 years.
We describe a comprehensive modeling framework
for economic evaluation of such a policy covering vac-
cination of all adults aged more than 50 years, on a
country-by-country basis. The model was designed to
inform decisions or preferences between the current
policy and the proposed new policy. The current policy
is pragmatically deﬁned as the actual per capita cov-
erage rate currently being achieved among people aged
50 to 59 or 64 years, whereas the new policy assumes
a coverage rate in this age group similar to that already
being achieved in those more than 60 to 65 years of
age. In this article, we present CEAs for three Euro-
pean countries and one middle-income country:
France, Germany and Italy, and Brazil, taking third-
party public payers’ and societal perspectives. The new
policy would extend coverage to patients aged 50 to
59 years in Brazil and Germany and 50 to 64 years in
France and Italy.
It is intended to report ﬁndings for further Euro-
pean and non-European countries in due course as
part of a continuing international study. Brazil is
included here as the largest South American economy
to provide a comparison with leading European states.
Because of the heterogeneity in economic development
and health-care in Brazil, the analysis is based on data
for São Paulo, the most populous state.
Methods
Model Speciﬁcation
We developed a decision-analytic model to assess, on a
country-speciﬁc basis, the cost-effectiveness of lower-
ing the age threshold for funding inﬂuenza vaccination
from the current level of 60 or 65 years to include all
people aged 50 years and more, compared with the
current policy of vaccinating only those aged 50 to 59
or 64 years who are at high risk of complications in
the event of contracting inﬂuenza.
We needed to distinguish between those at high risk
and low risk (hereafter “HRs” and “LRs,” respec-
tively) because the increase in vaccination rates
between the current risk-based and proposed age-
based policies is expected to differ according to risk
status. HRs are individuals with chronic conditions
associated with an increased risk of complication of
inﬂuenza-like illness (ILI). These conditions include
chronic respiratory disease, chronic heart disease
excluding uncomplicated controlled hypertension,
chronic renal disease, diabetes, and immunosuppres-
sion due to treatment or disease (e.g., systemic ster-
oids, HIV infection) [19]. All other individuals aged 50
to 59 or 64 years are categorized as LRs.
Although inﬂuenza vaccines afford protection only
against true inﬂuenza, the model is conservatively
based on ILI, rather than conﬁrmed inﬂuenza [20]. It is
impossible to ascertain the true incidence of inﬂuenza
in the community, as universal serological conﬁrma-
tion is not feasible. Moreover, some cases of true inﬂu-
enza are asymptomatic. In any case, much of the
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literature on epidemiological surveillance and health-
care resource utilization is based on ILI, so it was more
practical to estimate model parameters using this case
deﬁnition. According to the International Classiﬁca-
tion of Health Problems in Primary Care [21], a diag-
nosis of ILI should be made when at least one of the
three following conditions is veriﬁed:
1. Inﬂuenza virus culture positive or serological evi-
dence of inﬂuenza virus infection;
2. Context of inﬂuenza epidemic and four of the cri-
teria in (3) below;
3. Six of the following criteria: sudden onset (within
12 hours), cough, fever, chills, prostration and
weakness, myalgia or general pain, rhinitis, phar-
yngitis, and contact with a case.
European surveillance networks, however, use var-
iable deﬁnitions [22], and the model inputs for each
country are driven by available data.
The use of ILI as the case deﬁnition is supported by
the availability of appropriate efﬁcacy data for each
modeled event: occurrence of ILI, work absence, minor
complications, hospitalizations, and deaths. The
model takes account of the fact that complications are
less likely to occur in vaccinated than nonvaccinated
ILI cases. Vaccine efﬁcacy was considered similar
across  all  patient  groups,  as  there  is  little  evidence
for an association with age or presence of chronic
conditions.
The pathways of events considered in the model are
shown as a decision tree in Figure 1. Under each pol-
icy, the target population consists of HRs and LRs,
who may or may not be vaccinated and, as a conse-
quence, face differing probabilities of remaining
healthy or contracting ILI in the winter inﬂuenza sea-
son after vaccination. Patients with ILI choose whether
or not to seek medical help, and if so they may receive
symptomatic antiviral medication. The model includes
the effect of these drugs in reducing work absence and
risk of complications. Self-medication is not modeled,
because of the difﬁculty in estimating ILI-related over-
the-counter drug use. Patients may remain free of com-
plications and recover normally, incur a minor com-
plication, suffer a complication requiring hospital
admission, or die. For minor complications, such as
acute bronchitis, the costs of additional consultations,
tests, and antibiotics are taken into account, but no
longer-term health deﬁcit is assumed to occur. Hospi-
talizations are treated in three categories: pneumonia
and inﬂuenza, other respiratory complications, and
nonrespiratory complications, including circulatory
and diabetic problems. In the tree (Fig. 1), patients not
attending for ILI may survive or die, although it was
assumed for the countries studied here that deaths
Figure 1 Decision tree for inﬂuenza vaccination policies and consequences. Note: Repeating parts of the tree, or “subtrees” are omitted for clarity. At
the nodes marked “Clone 1:  Vaccination status subtree,” the omitted subtrees are identical to the entire subtree that emanates from the right of the bold
branch and node labeled “1.” At the node marked “Clone 2: ILI subtree,” the omitted subtree is identical to the entire subtree that emanates from the
right of the bold branch and node labeled “2.” A&E, accident and emergency; GP, general physician; ILI, inﬂuenza-like illness.
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occur only in patients who have received medical
attention.
An episode of ILI was assumed to result in a given
number of lost workdays speciﬁc to each country,
which did not vary according to vaccination status,
but did vary according to whether or not the patient
consulted his or her general practitioner (GP). Treat-
ment with antivirals was assumed to reduce the length
of absence.
Model Outcomes
The following categories of costs were considered from
the third-party payer (TPP) perspective:
• Cost of vaccination, including vaccine acquisition
and administration;
• Primary care costs for ILI patients: GP visits,
prescription drugs, diagnostic tests, and possible
referrals to a specialist in case of complication;
• Hospitalizations because of pneumonia, other
respiratory complications, or cardiovascular
complications;
• Sick-leave payments for countries where a single
agency funds both health care and sick leave, and
where payments are given even for short absences
(e.g., France).
The TPP perspective included only the share of total
health-care costs borne by third-party payers. It did
not include patient copayments. From the societal per-
spective, patient copayments were included, along
with the cost of absenteeism to employers. For France,
Germany, and Italy, costs are reported in Euros (€), for
the reference year 2003. For Brazil, costs are reported
in reals (R$). The mean nominal exchange rate in 2003
was R$3.07 per US dollar and R$3.52 per euro. All
costs were incurred within a single year, so the need for
discounting did not arise.
The model is designed to calculate several out-
comes: averted ILI cases, hospital admissions and
deaths, life expectancy in unadjusted life-years (LYs),
and quality-adjusted life-years (QALYs). QALYs were
calculated by applying weighting factors representing
the quality of life for each year of survival and sum-
ming over the number of years of life expectancy. In
the absence of age-speciﬁc norms for the countries
studied, we used proxy weights from the Health Sur-
vey for England 1996 for the base case [23] and from
the Canadian National Population Health Survey
(1996 for sensitivity analysis (see Table A1). Transient
reductions in quality of life because of inﬂuenza epi-
sodes were not considered, as these are short in
comparison with a lifetime. Any difference between
policies in the calculated number of QALYs would
therefore be attributable only to differences in inﬂu-
enza mortality rates and the resulting impact on life
expectancy. LYs and QALYs were discounted to
present values at 3% per annum [24]. Principal model
inputs are shown in Table 1. Most data were obtained
from the literature, national, or general statistical
sources (e.g., Organisation for Economic Co-operation
and Development, Eurostat), epidemiological surveil-
lance Web sites, and country-speciﬁc tariffs.
Sources of Data: Noncountry-Speciﬁc
We assumed that vaccine effectiveness does not differ
between countries and considered studies from any
country. Where parameters were thought to be coun-
try-speciﬁc, we sought local data but relied on data
from other countries as needed. The clinician authors
(JT-N, FC, PW, RG) validated inputs for their respec-
tive countries. All epidemiological data (ILI incidence,
hospitalization rates, case fatality rates) were speciﬁc
to people aged 50 to 60 or 64 years old.
A number of clinical effectiveness parameters were
required. The reduction in the number of ILI cases
because of vaccination was taken from a systematic
Cochrane review by Demicheli et al. [25]. The review
identiﬁed 10 trials published between 1966 and 1997
and reported that vaccination reduced the number of
clinical cases by 29% (95% conﬁdence interval (CI)
12–42%). The ﬁndings of more recent vaccine trials in
nonelderly adults (Campbell et al. (1997) [26], Nichol
et al. (1999) [27], Bridges et al. (2000) [10], and Villari
(2004) ) [28] are consistent with the systematic review.
A similar reduction of 29% was applied to the
probability of seeking medical attention for ILI, to the
use of antivirals and other medications (e.g., antibiot-
ics, analgesics), and to lost workdays (Table A2). This
was broadly consistent with the results of trials by
Nichol et al. (1995) [8], Nichol et al. (1999) [27], and
Bridges et al. (2000) [10]. We assumed that the per-
centage reduction in utilization of antivirals and other
medications (e.g., antibiotics, analgesics) is similar to
the percentage reduction in physician visits, which
would be true if vaccinated patients were treated in the
same way as nonvaccinated patients. Although intui-
tively the latter seem likelier to be treated as having
true inﬂuenza, results from Nichol et al. [27] and
Bridges et al. [10] suggest the assumption is accepta-
ble. For minor complications, we used the 28.1%
(95% CI 16.0–38.4) reduction reported by Nichol
et al. [27].
There have been relatively few studies [25,29] of the
effectiveness of inﬂuenza vaccines in preventing hospi-
talizations and deaths in nonelderly adults. We used
results of a meta-analysis of 20 cohort studies of the
effectiveness of the inﬂuenza vaccine in elderly persons
[30], which reported a reduction in hospital admis-
sions of 50% (95% CI 28–65%) and a reduction in
mortality of 68% (95% CI 56–76%).
Antiviral effectiveness parameters are shown in
Table A3. The reduction in lost workdays because of
antivirals was obtained from a large, multinational
trial of zanamivir versus placebo [31]. The reduction in
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antibiotic use was obtained from a systematic review
on zanamivir in the treatment of inﬂuenza in adults
[32]. Reductions in complication rates were obtained
from a systematic review of zanamivir and oseltamivir
[33]. As the prescribed proportions of the two antivi-
rals vary between countries, we used market share data
to calculate a weighted overall antiviral efﬁcacy rate
for each country.
Sources of Data: Country-Speciﬁc
Country-speciﬁc data included population size, life
expectancy, the proportion of HRs aged 50 to 59 or
64 years, the proportion currently eligible for vaccina-
tion, vaccination uptake under the current policy, the
inﬂuenza attack rate, propensity to seek medical atten-
tion for ILI, antiviral usage, probabilities of minor
complications and of requiring hospital admission,
and the case fatality rate. The base case inputs for each
country are shown in Tables A4–A11. Our approach
to gathering these inputs was to use published local
data as far as possible. To this end, the clinician
authors (JT-N, FC, PW, RG) completed a detailed,
structured questionnaire, identifying published sources
of country-speciﬁc information as far as possible.
Where country-speciﬁc data were not available, judg-
ments were made as to whether data from other coun-
tries was likely to be generalizable, or whether expert
opinion would be preferable. Sensitivity analyses were
performed where parameter inputs were uncertain.
Demographic data were taken from national sources.
Unit costs for each resource item were collected for
each country, along with the proportions of costs faced
by third-party payers compared with society as a
whole, to allow analyses from TPP and societal
perspectives.
Current vaccination coverage rates were obtained
from TNS Sofres market research surveys in the three
European countries [34] and from unpublished data
known to JT-N in Brazil. The model required the input
of coverage rates by risk status, as vaccination is
expected to be higher in HRs. A Spanish study, using
data from the 1997 National Health Survey, showed
that the uptake in HRs aged 50 to 64 years was 2.44
times higher than the uptake in LRs in the same age
group. Based on this information and the proportion
of HRs, vaccine coverage rates were calculated for
Germany and Italy. In France, the vaccination uptake
in HRs (individuals younger than 65 but eligible for
Table 1 Model input values
Parameter Base case input value (SD) Alternative values
Type of 
distribution Source
Discount rate (%) 3 0, 5, 8, 10 depending on country
Incidence of ILI consultations (%) Varies between countries 
(approximately 5, SD 2.3)
25 and 185 of base case Empirical [15;60–62]
Probability of hospitalizations 
(Germany/France/Italy, %)
HR: 11.3 (0.9)−13.4 (1.0)
LR: 1.4 (0.4)−1.6 (0.5)
HR: 044; LR: 0.04
HR: 6.47–8.04; LR: 0.69–0.85
HR: 10.69; LR: 2.38
Beta [63,64]
Probability of hospitalizations 
(Brazil, %)
HR: 3.05 (1.12); LR: 0.33 (0.12) HR: 0.44; LR: 0.04
HR: 2.11; LR: 0.23
HR: 3.11; LR: 0.34
HR: 4.74; LR: 0.52
HR: 10.69; LR: 2.38
Lognormal [64,65]
Probability of death (%) HR: 0.826 (0.222)−1.023 (0.247)
LR: 0.015 (0.029)−0.017 (0.031)
HR: 0.241; LR: 0.081
HR: 1.005–1.249; LR: 0.009–0.011
HR: 1.063–1.322; LR: 0.009–0.012
[1,4,39,64]
Elasticity of labor to production (%) 100 80 —
Vaccine efﬁcacy: reduction in 
incidence of ILI consultations (%)
29 (8) 12–42 Lognormal [25]
Vaccine efﬁcacy: reduction in excess
incidence of hospitalizations (%)
50 (11) 28–65 Lognormal [30]
Vaccine efﬁcacy: reduction in excess 
mortality (%)
68 (5) 56–76 Lognormal [30]
Utilities Based on EQ-5D norms, Health 
Survey for England, 1996
Based on HUI3 norms, National Population 
Health Survey, 1996 (Canada)
— [66]
Time off work for vaccination None 1 hour per vaccine in full-time 
employment
—
Vaccine administration, LR–France 
(%)
Routine visit: 18.3 (7.9)
Special visit: 73.2 (8.0)
Occupational visit: 8.5 (1.4)
Routine visit: 40
Special visit: 20
Occupational visit: 40
Triangular [67,68]
Vaccine price–Germany (€) 7.00 (0.55) 5.00, 9.00 Triangular [69]
Vaccine price–Italy (€) 6.57 (0.45) 5.00, 10.00 Triangular
Vaccine administration cost, societal 
perspective–Brazil (R$)
3.58 (2.68) 0.50, 10.00 Gamma [15,70]
HR, patients at high risk of complications; HUI3, Health Utilities Index mark 3; ILI, inﬂuenza-like illness; LR, patients at low risk of complications.
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free vaccination) was known from national insurance
data [35,36]. Coverage in LRs was calculated using
known rates for HRs and the aggregate population. In
Brazil, the VigiGripe study reported that the vaccina-
tion coverage rates in the public sector were 12% in
HRs and 2% in LRs [37].
Vaccination uptake under the proposed policy was
assumed be equal to current uptake in people more
than 65 years (more than 60 years in Germany and
Brazil). Studies have suggested that when entire age
groups are targeted for routine vaccination, coverage is
approximately 30% higher in people with high-risk
chronic conditions than in those without [38–40]. We
used this assumption to apportion coverage between
HRs and LRs across the 50 to 59 or 64 years age
group. In Brazil, coverage rates of 75% and greater
have been reported in people aged more than 65 years
[41]. We considered that such high levels of coverage
are unlikely to be reached in the 50 to 64 years age
group. Therefore, we based assumed coverage rates on
a reported Brazilian government target of 70% [42].
Unit costs of resource items, including vaccine and
administration, consultations for ILI, and clinical
consequences and lost productivity, were obtained
from national sources (see Table A10 and Table A11).
Analyses from the TPP perspective were based on the
reimbursed portions only of unit costs.
Economic Analyses
Expected costs, outcomes and incremental cost-
effectiveness ratios (ICERs) were calculated for each of
the four countries and perspectives. ICERs were
reported as mean cost per QALY gained for the pro-
posed versus current policy. Deterministic sensitivity
analyses were performed on key model inputs, subject
to scenario or parameter uncertainty, to determine the
individual impact of alternative assumptions. Base case
inputs and alternative values are shown in Table 1.
Probabilistic analyses were performed by Monte
Carlo simulation to propagate the joint effects of
parameter uncertainty through the model. Again, these
were carried out for all four countries and both ana-
lytic perspectives. For variables based on sample dis-
tributions, such as the meta-analysis of efﬁcacy rates,
we applied the reported parameter values to an appro-
priate distributional form [43]. For some inputs, we
were obliged to specify distributions subjectively, in
the absence of empirical evidence. For example, we
speciﬁed the proportion of HRs as a triangular distri-
bution around estimates of the extreme and mean val-
ues. The model inputs speciﬁed as distributions, along
with the distributional forms and parameters used, are
listed in Table A12. Mean incremental costs and incre-
mental QALYs, along with 95% credible intervals
using the 2.5th and 97.5th percentile values, were
derived from the Monte Carlo simulations. The indi-
vidual simulated pairs of incremental cost and QALY
values were used to generate cost-effectiveness accept-
ability curves.
The underlying prevalence of inﬂuenza viruses in
the winter months varies widely from year to year,
with a relatively low number of true inﬂuenza cases in
some years and epidemics in others. To model this nat-
ural ﬂuctuation, we used an empirical distribution of
historical ILI incidence as the best available data to
predict future incidence. The INSERM surveillance
network in France provides estimates of the incidence
of ILI consultations for the years 1985 to 2002 among
people aged 50 to 59 years. These range from 1.2% to
8.7%, with an average of 4.7% (compared with an
average annual incidence of 6.1% in the overall pop-
ulation). This distribution was used for the French
analysis. Local surveillance data for the other three
countries were adjusted for age, and historical distri-
butions were estimated using the INSERM data. It is
notable that average annual attack rates from surveil-
lance are much lower than those reported in clinical
trials [25], and provide conservative estimates for this
model.
These attack rate estimates could not be used
directly, as they come from populations with a non-
negligible proportion of vaccinated persons, and there-
fore underestimate the probability of ILI in the unvac-
cinated proportion. The incidence of ILI consultations
in the unvaccinated population was derived from the
observed incidence, the vaccination uptake during the
observation period, and vaccine efﬁcacy. For example,
in France, where the observed average incidence was
4.69%, the overall vaccine uptake was 21.1%, and the
effectiveness on ILI was 29%, the incidence of ILI, I, in
unvaccinated persons was calculated as:
Results
Base-Case Analyses
The results of the incremental CEAs are shown in
Table 2. The mean ICERs for Brazil, France, Germany,
and Italy are approximately R$4100, €13,200,
€31,400, and €15,700 per QALY gained, respectively,
from a TPP perspective. From a societal perspective,
the new policy would cost R$2800 per QALY gained
in Brazil and €8000 per QALY gained in France,
whereas it would dominate the current policy in Ger-
many and Italy.
Using the assumed rates of population coverage, the
proposed policy would avert approximately 80,000
cases of ILI per year in Brazil, 116,000 cases in France,
54,000 cases in Germany and 96,000 in Italy. This
would translate into approximately 210, 440, 120,
and 230 deaths avoided annually in these four coun-
tries, respectively. Detailed results on the outcomes
expressed as ILI cases, hospital admissions, deaths and
I =
− ∗( ) =
4 69
1 21 1 29
5 00
.
.
.
% %
%
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lost productivity are shown in Table 3. To achieve
these outcomes, the incremental cost would be approx-
imately R$10 million in Brazil, €71 million in France,
€47 million in Germany and €44 million in Italy, from
a TPP perspective. From a societal perspective, the cost
diminishes to R$7 million in Brazil and €43 million in
France, whereas in Germany and Italy the proposed
policy would generate cost savings of €15 million and
€2 million, respectively. These costs are broken down
in Table 4 by their main components: vaccination, pri-
mary care costs, hospital costs, and lost productivity.
The cost results for Brazil are quite distinct from the
European countries, reﬂecting the signiﬁcantly lower
unit costs of resources in Brazil. From the Brazilian
TPP perspective, the mean incremental cost per person
vaccinated is R$3.41 (approximately €1 at 2003
exchange rates). The comparable ﬁgures in European
countries fall in a narrow range: €6.66 in France,
€4.73 in Germany and €4.07 in Italy. The respective
mean costs from a societal perspective are R$2.12,
€4.04, €−1.51 and €−0.17, indicating that the pro-
posed policy is expected to be cost-saving to society in
Germany and Italy. The variation among countries in
the reported number of QALYs gained reﬂects the dif-
fering uptake rates assumed in each country, which
were predicated on vaccination uptake in each country
under the current risk-based policy.
The differing results among countries are partly
driven by differences in population size. Another
major driver is the increase in vaccine uptake, more
speciﬁcally for individuals at high risk of complica-
tions. In France, where the current eligibility criteria
are very restrictive (4.7% of the 50- to 64-year-olds are
assumed currently eligible for vaccination in France,
vs. 25% in Italy), the potential for improvement of
vaccine uptake in HRs is very high. In Brazil, the exist-
ing level of coverage is very low, for both risk groups,
and is expected to reach 70% under the new policy, so
that the expected increase of vaccination coverage
rates is also substantial, for HRs in particular. As a
result, France and Brazil are the two countries with the
greatest expected average QALY gains. In Germany,
Table 2 Results of cost-effectiveness analysis
Perspective Country Policy
Costs QALYs (discounted at 3% per annum)
ICER mean 
incremental 
cost per 
QALY gainedUnits
Total 
mean
Incremental 
mean
(2.5th; 97.5th 
percentile) Total
Incremental 
mean
(2.5th; 97.5th 
percentile)
Third-party
payer
Brazil Current R$ (millions) 6.50 41,006,895
Proposed 16.91 10.41 (9.06; 11.27) 41,009,449 2,554 (593; 6,011) 4,075
France Current € (millions) 90.61 128,999,864
Proposed 161.37 70.8 (44.86; 92.21) 129,005,243 5,379 (1,182; 12,801) 13,156
Germany Current € (millions) 79.20 131,175,999
Proposed 125.93 46.73 (37.20; 55.35) 131,177,634 1,636 (310; 3,805) 31,387
Italy Current € (millions) 95.96 131,333.729
Proposed 139.98 44.02 (26.83; 58.69) 131,336,541 2,812 (598; 6,691) 15,652
Societal Brazil Current R$ (millions) 56.38 41,006,895
Proposed 63.55 7.17 (−8.23; 21.71) 41,009,449 2,554 (593; 6,011) 2,805
France Current € (millions) 369.07 128,999,864
Proposed 412.04 43.0 (−22.31; 91.04) 129,005,243 5,379 (1,182; 12,801) 7,989
Germany Current € (millions) 389.18 131,175,999
Proposed 374.26 −14.93 (−45.45; 5.96) 131,177,634 1,636 (310; 3,805) Dominant
Italy Current € (millions) 333.92 131,333.729
Proposed 332.13 −1.79 (−37.36; 25.10) 131,336,541 2,812 (598; 6,691) Dominant
ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life-years.
Table 3 Health and economic outcomes of proposed policy, by country
Country Policy
ILI cases Hospital admissions Deaths Lost productivity
Total 
cases
Cases 
averted
Total 
admissions
Admissions
averted
Total 
deaths
Deaths
averted
Workdays
lost
Loss avoided
(days)
Brazil Current 422,193 1,869 486 413,211
Proposed 341,939 80,254 1,281 589 276 210 333,094 80,116
France Current 877,324 19,773 1,078 1,146,117
Proposed 761,160 116,164 14,421 5,352 635 443 994,380 151,737
Germany Current 814,976 16,512 878 1,162,824
Proposed 760,809 54,167 14,819 1,693 755 123 1,085,506 77,319
Italy Current 979,956 19,854 989 1,145,324
Proposed 884,143 95,813 16,619 3,235 758 232 1,033,343 111,981
ILI, inﬂuenza-like illness.
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the assumed overall increase in coverage, particularly
among HRs, is less than that in the other countries,
resulting in a correspondingly smaller gain in QALYs.
Health gain is strongly related to the improvement of
vaccination uptake in the HR group.
As noted earlier, the adoption of a societal rather
than a TPP perspective enhances the cost-effectiveness
of the new policy in all four countries. As Table 4
shows, this is due to net reductions in incremental
costs, although their magnitude and breakdown differs
markedly between countries. The inclusion of the
impact on productivity losses contributes favorably to
cost-effectiveness in all four countries, but this effect is
modiﬁed in differing directions by national variations
in payment arrangements for additional vaccine
coverage.
In Brazil, there is a high degree of variability in the
cost-to-charge ratio for vaccine administration. This
introduces uncertainty into the societal results, which
are based on costs rather than charges. In Germany
and Italy, the incremental societal cost of expanding
vaccination is mitigated by the fact that under the cur-
rent policy noneligible individuals purchase vaccine at
prices much higher than contract prices that third-
party payers could negotiate under the proposed pol-
icy. Furthermore, under the ﬁnancing assumptions
used in this analysis, although newly covered persons
in France would receive the vaccine free of charge, they
would face a 30% copayment for the cost of an addi-
tional primary care visit for vaccination. The small
proportion of Italians opting for vaccination in the pri-
vate sector would face the full cost of vaccination and
physician visit, whereas patients covered in Germany
would bear none of the vaccination costs at all. The net
impact of these variations is to reverse the ordering of
results between perspectives among the European
countries. From a TPP perspective, the new policy was
most cost-effective in France, then Italy, then Germany,
but from a societal perspective the new policy was
clearly dominant in Germany, just dominant in Italy,
and not dominant in France. The incremental societal
costs of the new policy would be lowest in Germany
and highest in France among the European countries.
Another variation between countries is the relative
cost of vaccination between new and existing policies.
In France, most current visits for vaccination are
opportunistic, so the cost is lower than it would be for
vaccination-speciﬁc visits under the new policy. In Ger-
many and Italy, however, signiﬁcant numbers of non-
eligible persons currently choose to be vaccinated, in
spite of facing a higher cost than public payers incur
on behalf of eligible vaccinees.
Deterministic Sensitivity Analyses
Deterministic sensitivity analyses were carried out on
all variables, subject to decision or parameter uncer-
tainty. By far the most sensitive input was the attack
rate, i.e., the incidence of ILI consultations, regardless
of country or perspective. As Figure 2 shows, the ICER
for all three of the European countries fell below
€50,000 per QALY gained from a TPP perspective pro-
vided the attack rate exceeded 3%, which was true in
13 of the 18 years of INSERM surveillance data
between 1985 and 2002. Greater proportions of the
population at high risk of complications from ILI and
higher death rates after consultation for ILI produced
lower ICERs. These were the three most sensitive
inputs, regardless of country perspective. The results
were moderately sensitive to the choice of discount
rate, lower rates producing lower ICERs, and the
uptake rate of the new policy, for which higher rates
resulted in lower ICERs.
From the societal perspective, assumptions concern-
ing the numbers of workdays lost to ILI were moder-
Table 4 Total cost breakdown of current and proposed policies at population level, by country
Country Perspective Policy
Vaccination Primary care Hospitalization Lost productivity Total
Absolute Difference Absolute Difference Absolute Difference Absolute Difference Absolute Difference
Brazil TPP Current 0.9 5.0 0.6 0 6.5
Proposed 12.4 11.5 4.1 −0.9 0.4 −0.2 0 0 16.9 10.4
Societal Current 1.4 15.1 4.4 35.4 56.4
Proposed 19.7 18.3 12.3 −2.8 3.0 −1.4 28.6 −6.9 63.5 7.2
France TPP Current 7.3 13.8 62.7 5.9 90.6
Proposed 97.8 90.5 11.9 −1.8 45.7 −17.0 6.8 −0.9 161.4 70.8
Societal Current 23.9 21.1 75.8 248.3 369.1
Proposed 123.0 99.2 18.3 −2.8 55.3 −17.0 215.4 −32.9 412.0 43.0
Germany TPP Current 5.1 11.3 62.6 0 79.2
Proposed 59.0 53.9 10.6 −0.7 56.3 −6.4 0 0 125.9 46.7
Societal Current 49.0 13.1 64.3 262.8 389.2
Proposed 59.0 10.0 12.2 −0.8 57.7 −6.6 245.3 −17.5 374.3 −14.9
Italy TPP Current 13.5 13.7 68.9 0 96.0
Proposed 69.9 56.5 12.4 −1.3 57.7 −11.1 0 0 140.0 44.0
Societal Current 56.8 15.1 73.2 188.9 333.9
Proposed 86.8 30.1 13.7 −1.5 61.2 −11.9 170.4 −18.5 332.1 −1.8
Brazil data in R$ millions, France, Germany, and Italy in € millions, rounded to nearest 0.1 million.
TPP, third-party payer.
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ately inﬂuential. Attendance for vaccination was
assumed to have no effect on productivity in the base-
case analysis, as patients would be expected to make
up for time off work or be vaccinated outside normal
working hours. We used a maximum loss of 1 hour
for sensitivity analyses, although several US studies
[10,44,45] have assumed a productivity loss of
30 minutes.
Some variables had a country-speciﬁc inﬂuence. In
France, the vaccine administration setting was partic-
ularly inﬂuential, as the base case assumption for the
cost of vaccination reﬂects the current practice that
physicians rather than nurses administer the vaccine.
In Brazil, the cost of vaccine administration is substan-
tially higher in the private sector, making results sen-
sitive to the setting.
Results of the deterministic sensitivity analyses, as
exempliﬁed by France, are shown as tornado charts
in Figure 3 (TPP perspective) and Figure 4 (societal
perspective).
The cost-effectiveness acceptability curves pre-
sented in Figure 5 illustrate that if European third-
party payers were to value a QALY at €50,000, then
the probabilities of the proposed policy being cost-
effective would be 94% in France, 89% in Italy,
and 72% in Germany. If a QALY were valued at
€50,000 to society at large, then the probabilities of
the new policy being cost-effective would increase to
95% in France, 99% in Italy, and 100% in Ger-
many. Although, as stated earlier, there have been
no public statements on the value of a QALY in
Brazil, a conservative ceiling value might be the
value of the gross domestic product (GDP) per cap-
ita in that country. Using the 2003 ﬁgure of R$8558
(€2431) per QALY gained, the proposed policy
would be cost-effective with a probability of 83%
from the TPP perspective, and 79% from the soci-
etal perspective.
Discussion
Inﬂuenza vaccination is currently recommended for
adults with high-risk chronic conditions as well as all
people aged 65 years or older in France and Italy, and
those aged 60 years or older in Germany and Brazil.
We assessed the cost-effectiveness of a proposed new
policy to vaccinate all individuals aged 50–64 years
(59 years for Germany and Brazil) compared with the
current policy of targeting only high-risk persons in
this age group. The population targeted in this evalu-
ation, i.e., people aged 50 to 64 years, includes a large
proportion of individuals at increased risk of compli-
cations, as well as a large proportion of working indi-
viduals. The ACIP recommends vaccination for people
aged 50 to 64 years but also points out the lack of
cost-effectiveness studies for that age group [46]. We
assessed the cost-effectiveness, budgetary impact, and
health gains likely to result from an increase in vacci-
nation coverage beyond levels achieved under current
existing policies, with a view to providing decision-
makers with the economic comparison that they face
in actual practice.
We estimate that the incremental cost per QALY
gained for the proposed versus current policy would be
R$4,100, €13,200, €31,400 and €15,700 for Brazil,
France, Germany, and Italy, respectively, from a TPP
perspective. From the societal perspective, the pro-
posed policy is predicted to yield net cost savings in
Germany and Italy, whereas the cost per QALY
decreased to R$2800 for Brazil and €8000 for France.
Given a cost-effectiveness ceiling ratio of €50,000 per
QALY gained, the probabilities of the new policy being
Figure 2 Impact of average annual ILI inci-
dence on incremental cost-effectiveness ratios.
ICER, incremental cost-effectiveness ratio; ILI,
inﬂuenza-like illness; QALY, quality-adjusted life-
year; TPP, third-party payer.
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cost-effective were 94% and 95% for France, 72%
and near 100% for Germany, and 89% and 99% for
Italy from the TPP and societal perspectives, respec-
tively. If the Brazilian GDP per capita in 2003 of
R$8558 (€2431) were taken as a possible ceiling value,
the new policy would be cost-effective with a proba-
bility of 83% from the TPP perspective, and 79% from
the societal perspective in that country. Differences
among countries were mainly driven by vaccination
uptake rates, vaccine administration costs, and ﬁnanc-
ing arrangements. This analysis conﬁrms the ﬁndings
of previous published economic evaluations, which
have established economic advantages of inﬂuenza
vaccination [7,9,33,44,47].
In this study, we used a reported rate of efﬁcacy
from a meta-analysis [25] of clinical trials of inacti-
vated vaccines, using ILI as the end point. At face
value, the efﬁcacy of 29% appears surprisingly low,
but it must be remembered that in a majority of con-
sultations for ILI, the infection is not true inﬂuenza.
The efﬁcacy of vaccination against serologically con-
ﬁrmed cases of inﬂuenza was estimated at 68% in the
same review. As much of the literature informing this
model necessarily uses a case deﬁnition of ILI, because
of the infeasibility of laboratory conﬁrmation of inﬂu-
enza in large, community-based studies, we were
obliged to use this end point also. Since our analysis
was conducted, an update of the Cochrane review on
which the vaccine efﬁcacy assumptions were based has
been published [48]. Although the data are not pooled
in exactly the same manner, the updated study suggests
an efﬁcacy of approximately 26% or 27% compared
with 29% in the original review. In light of the sensi-
tivity analyses performed on vaccine efﬁcacy, the
impact of using the updated data would be a small
increase in the estimated ICERs.
Most evaluations in nonelderly adults have concen-
trated on healthy working persons. These studies
reported cost savings, largely related to avoided loss in
workdays, but used less conservative assumptions for
the efﬁcacy of vaccination. Nichol [49] assumed an
incidence of inﬂuenza illness of 5% but a vaccine effec-
tiveness of 75%, and Lee et al. [44] assumed an inci-
dence of inﬂuenza illness of 15% and an effectiveness
of 68%. Our ﬁndings were similar when higher efﬁ-
cacy rates were used in sensitivity analyses.
A feature of this study is its pragmatic view on the
coverage likely to be achieved under the new policy.
Although all persons more than 50 years old would be
eligible for vaccination, it seems unlikely that this
would be achieved without a signiﬁcant increase in
health promotion efforts. We assumed that uptake
rates would be equivalent to the reported level of cov-
erage achieved in people in the higher age groups who
Figure 3 Tornado chart of univariate sensitivity analyses: France, TPP perspective. Note: ranges of input values shown in parentheses correspond to the
order of ICER values represented by ends of bars. Asterisked values are base case inputs. HR, patients at high risk of complications; HUI3, Health Utilities
Index mark 3; LR, patients at low risk of complications. 
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Figure 4 Tornado chart of univariate sensitivity analyses: France, societal perspective. Note: ranges of input values shown in parentheses correspond
to the order of ICER values represented by ends of bars. Asterisked values are base case inputs. HR, patients at high risk of complications; HUI3, Health
Utilities Index mark 3; LR, patients at low risk of complications. 
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Figure 5 Cost-effectiveness acceptability curves. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; TPP, third-party payer.
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are eligible under current policy. Higher uptake rates
could be modeled if evidence could be found for the
marginal costs and impact of health promotion efforts.
A recent study [50] concluded that comprehensive
vaccination of the elderly is cost-effective, although
less so than opportunistic vaccination. That study,
however, did not report the marginal cost-effectiveness
between an opportunistic and a comprehensive strat-
egy, which would seem to be the pertinent question for
decision-makers.
Although this study suggests inﬂuenza vaccination
is likely to be cost-effective from the restricted perspec-
tive of third-party payers, the case for the proposed
policy is strengthened when a more comprehensive
societal viewpoint is taken. It is well known that the
opportunity cost of lost productivity due to ILI is sub-
stantial, and we estimated this from two studies [8,10]
that speciﬁcally considered this question, as the 2001
Cochrane review [25] included, along with one [8] of
these, two old studies that we did not consider repre-
sentative. Productivity effects, however, apply not only
to time saved due to averted illness but also to the time
required for the vaccination itself. Workplace vaccina-
tion can minimize time lost in travel and disruption to
normal working patterns. Delegating vaccine adminis-
tration to staff whose time carries a lower opportunity
cost can allow coverage to be expanded more efﬁ-
ciently; indeed it may be a practical necessity.
This study has a number of limitations, mainly
because of lack of available data. Although there is a
vast literature on the epidemiology of inﬂuenza, data
were not always available in the form required for the
model, and we were obliged to make judgments in
adjusting data, for example in estimating coverage
among LRs and HRs from aggregate data. There are
few studies reporting the effectiveness of vaccines in
averting hospital admissions and deaths in nonelderly
adults, so we were obliged to use published evidence
relating to elderly persons for the relative risk reduc-
tion. Since carrying out the analysis, however, a large,
case-control study (PRISMA) [51] from The Nether-
lands of adults aged 18 to 64 years has appeared,
which suggests our assumptions are conservative.
PRISMA found a 78% reduction in deaths and an
87% reduction in hospital admissions, compared with
our base case assumptions of 68% and 50%, respec-
tively. Although the model is sensitive to several
parameters including vaccine efﬁcacy, by far the most
inﬂuential factor is the annual attack rate. The uncer-
tainty due to the natural variation in attack rate,
among the other sources of sampling uncertainty, is
captured in the cost-effectiveness acceptability curves
and the distributions of net monetary beneﬁts. This
presentation provides an explicit basis for policymak-
ers to consider the proposed policy according to their
criteria for cost-effectiveness and the degree of uncer-
tainty they are prepared to accept.
A further improvement would be to account for the
impact of illness on health-related quality of life. In the
CEA undertaken by Turner et al. [33], an episode of
symptomatic inﬂuenza caused a loss of 3.71 quality-
adjusted life-days. Also, in that analysis, the gain in
QALYs for healthy adults was caused by the impact of
vaccination on quality of life. The fact that patients
who die from inﬂuenza complications may be less
healthy than average, and therefore would have lower
utilities as well as lower life expectancy, was not mod-
eled, as this effect was not possible to quantify. Age-
speciﬁc utility values were only available from England
and Canada and might be overestimates for Brazil,
where life expectancy is lower and health is likely to be
worse at a given age. Potential adverse effects of vac-
cination are not represented in the model, as these are
generally local reactions with no associated cost and
little impact on quality of life. In a review of several
studies by Turner et al. [33], there was no statistically
signiﬁcant difference in reported reactions between
vaccine and control arms. We applied conventional
practice [24] to the discounting of health effects. An
alternative approach has recently been proposed for
preventive interventions [52] in which risk reduction is
discounted from the time of intervention, which would
lead to more favorable cost-effectiveness ratios.
Our study was designed to inform a decision
between the current policy of providing selective vac-
cination for persons aged 50 to 59 or 64 years and the
proposed policy, which would cover all persons in this
age group, thus increasing the demand for vaccine. The
ﬁxed costs that vaccine manufacturers would incur in
stepping up capacity mean that a policy of selecting
target groups on a year-by-year basis is not feasible.
Therefore, the policy decision has to be a “once and
for all” consideration that takes into account the
natural annual variation in attack rate. Our cost-
effectiveness estimates are based on an interpandemic
period from 1985 to 2002. It is a certainty that at some
point in the future, a pandemic will occur. Pandemic
inﬂuenza can result from a phenomenon known as
“antigenic shift,” involving an abrupt change in the
surface glycoproteins in an emergent strain of inﬂu-
enza A virus to which the human population has no
immunity. This occurred from 1918 to 1919, causing
an estimated 40 million to 50 million deaths world-
wide, and more recently in 1957 and 1968. Pandemics
can also result from viral strains, such as avian inﬂu-
enza, crossing the species barrier. With the entire pop-
ulation lacking immunity and susceptible to infection,
it would be imperative to expand vaccination, ideally
to achieve full coverage. Nevertheless, unless vaccine
manufacturing capacity was sufﬁcient, it would not be
possible to cover the whole population and prioritiza-
tion would be necessary. An important beneﬁt of the
proposed policy to expand coverage to all persons
aged more than 50 years is that it would entail an
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increase in interpandemic vaccine use and encourage
manufacturers to step up capacity, thus enabling more
people to be vaccinated during a pandemic. This
would probably not be sufﬁcient, but at least would be
a step in the right direction. The World Health Organ-
ization (WHO) has developed a pandemic prepared-
ness plan, a key feature of which is to address the
shortage of vaccine when “ideally, sufﬁcient vaccine
should be available for the whole population.” The
WHO notes “production and use of vaccines during
the interpandemic period will inﬂuence their availabil-
ity during a pandemic, by improving the infrastructure
for vaccine production and administration, and by
improving public and professional familiarity with
inﬂuenza vaccine.” History indicates that there is no
regular pattern to pandemics and, in spite of surveil-
lance programs, there is no reliable basis for predicting
when a pandemic might occur.
The use of economic evaluation to inform decision-
making is steadily expanding from its traditional base
in Europe, North America, and Australia. A recent
study [53] reviewed the use of economic evaluation in
Latin America, with Brazil the highest producer of
published studies, including four concerned with vac-
cination [15,54–56]. Hence, it was timely to include a
Latin American country within this international
project. This study should enable decision-makers to
consider the local and international economic consid-
erations for a possible expanded vaccination policy,
alongside the much-publicized public health issues of
improving control of annual inﬂuenza epidemics and
preparing for a pandemic [57,58].
Subject to decision-makers’ valuations of a QALY,
we conclude that targeting all people aged 50–64 years
for inﬂuenza vaccination is likely to be cost-effective in
the four countries studied. This conclusion applies
whether a TPP or a societal perspective is taken, but
especially so from the latter. The new policy is pre-
dicted to yield net cost savings to society in Germany
and Italy. Even from a narrower, TPP viewpoint, how-
ever, the cost-effectiveness ratios reported here are
within the range reported for other interventions
accepted in European countries. For Brazil, the new
policy would generate QALYs at a cost lower than the
annual GDP per capita, arguably a conservative crite-
rion for cost-effectiveness of the proposed policy. Our
results are consistent with the existing international lit-
erature, reviews of which [7,59] have concluded that
inﬂuenza vaccination is likely to be cost-effective or
cost-saving in healthy, working adults.
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Appendices
Table A1 Utility values by age group
Age group
(years)
Base case:
Health Survey for England [66]
1996
Sensitivity analysis:
Canadian NPHS*
1996
50–54 0.85 0.89
55–59 0.79 0.87
60–64 0.79 0.87
65–69 0.78 0.86
70–74 0.78 0.83
75–79 0.73 0.78
80–84 0.73 0.72
85+ 0.73 0.58
*Jean-Marie Berthelot, 2005, pers. comm.
Table A2 Model inputs: vaccine effectiveness
Efﬁcacy parameter Reduction (%)
Incidence of ILI [25] 29
Probability of GP visit* 29
Probability of prescription of ﬂu treatment* 29
Probability of prescription of other treatment* 29
Probability of stopping work* 29
Probability of minor complication* [27] 28
Probability of hospitalization* [30] 50
Probability of death* [30] 68
*Reductions are modeled as unconditional on presence of inﬂuenza-like illness (ILI).
GP, general physician.
Table A3 Model inputs: antiviral effectiveness
Reduction in:
Oseltamivir 
(%)
Zanamivir 
(%)
HR LR HR LR
Probability of absence from work [31] 13 13 13 13
Probability of antibiotic use [32] 6 27 6 27
Probability of minor complication [33] 34 58 44 26
Probability of hospitalization [33] 25 84 33 64
Probability of death [33] 29 74 29 64
HR, patients at high risk of complications; LR, patients at low risk of complications.
Table A4 Populations considered, by age subgroup, in 2003
Age (years) Brazil (São Paulo)* France Germany Italy
50–54 1,899,953 4,254,104 5,428,591 3,815,499
55–59 1,475,451 3,704,782 4,453,475 3,529,011
60–64 NA 2,672,132 5,681,618 3,463,235
Total 3,375,404
(50–59)
10,631,018 9,882,066
(50–59)
10,807,745
*Estimates for Brazil are for 2002.
NA, not applicable.
Table A5 Life expectancy in years by age, in 2000
Age (years) Brazil France Germany Italy
50–54 25.6 29.8 29.6 31.3
55–59 21.6 25.5 25.2 26.9
60–64 17.9 21.4 20.9 22.6
Source: OECD Health Data, Paris: OECD/CREDES.
Table A6 Consultation, prescribing, and outcomes for ILI
Brazil 
(%)
France
(%)
Germany
(%)
Italy
(%)
Probability of seeking
medical attention, 
given ILI symptoms
40 [15] 57 [71] 53 [71] 60 [72]
Average annual 
incidence of ILI 
consultations in
unvaccinated 
persons*
5.07 5.00 4.70 5.84
At ILI consultation, 
proportion 
prescribed antiviral†
HRs 0 6 [71] 20 0
LRs 0 4 [71] 15 0
After ILI consultation, 
proportion of 
cases resulting in
Minor complication 
[63,73]
HRs 17.3 17.3 17.3 17.3
LRs 13.6 13.6 13.6 13.6
Hospital admission 
[1,64]
HRs 3.01 13.2 14.1 11.4
LRs 0.33 1.3 1.4 1.1
Death [39,64,74] HRs 0.950 0.963 1.028 0.826
LRs 0.009 0.009 0.009 0.008
*France: INSERM, Réseau Sentinelles, average over period 1985–2002 for 50–59 age
group. Adjusted from total to unvaccinated population. Other countries based on
same source, adjusted for propensity to seek medical attention.
†IMS monthly MIDAS data, quoted with permission from IMS Health. Average costs
of antivirals based on country-speciﬁc prices of oseltamivir and zanamivir weighted
by market shares.
HRs, patients at high risk of ILI complications; ILI, inﬂuenza-like illness; LRs, patients
at low risk of ILI complications.
Table A7 Numbers of missed workdays and workforce par-
ticipation rates by country
Brazil France Germany Italy
Missed workdays [71,72,75]
Consulting cases 3.8 3.7 3.8 4.8
Nonconsulting cases 0.3 0.3 0.3 0.3
Workforce participation 
rates (%), by age (years)*
50–54 58.9 76.7 74.6 62.6
55–59 52.4 57.4 58.8 39.4
60–64 NA 15.6 22.8 18.8
*OECD, 2002 (France, Germany, Italy); IBGE, PNAD-2002 (Brazilian National
Household Survey).
Table A8 Proportions of persons with high-risk conditions
and eligible for vaccination reimbursement
Brazil
(%)
France
(%)
Germany
(%)
Italy
(%)
Proportion of persons:
At high risk of complications 
(HRs)
30 25 [39] 25 [39] 25 [39]
Currently eligible for 
vaccination reimbursement*
30 5 10 25
Vaccination uptake
Current uptake under current policy‡
Proportion of HRs vaccinated 12 27† 39 42
Proportion of LRs vaccinated 2 19 16 17
Forecast uptake under new policy
Proportion of HRs vaccinated 70 77 53 67
Proportion of LRs vaccinated 70 60 41 51
*Assumed same proportion as HRs, expert opinion for France and Germany.
†CNAMTS, http://www.ameli.fr
‡TNS Sofres survey data for season 2002/3 for France, Germany, Italy. Brazil: Unpub-
lished data from Dr. Toniolo-Neto, based on UNIFESP study.
HRs, patients at high risk of ILI complications; LRs, patients at low risk of ILI com-
plications.
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Table A9 Primary care and outpatient resource utilization
Brazil France Germany Italy
GP visits for ILI
No. of visits 1 1.2 [71] 1 1
% visits at home, HR 10 20.4 8 20
% visits at home, LR 5 20.4 5 10
Minor complications
Pneumonia and inﬂuenza
No. of GP visits (HR, LR) 4, 2 3, 2 5, 4.5 4, 4
% home visits (HR, LR) 25, 50 50, 20 30, 20 70, 60
Tests, HR Complete blood count, 
chemistry panel, x-ray: 100%
Chest x-ray: 80% ESR, leucocytes x-ray,
ECG, CRP: 80%
Blood, urine, x-ray: 100%
Tests, LR Complete blood count, arterial
blood gases, chest x-ray: 80%
Chest x-ray: 80% As above As above
Other respiratory illnesses
No. of GP visits (HR, LR) 3, 2 2, 2 3.5, 3 2, 2
% home visits (HR, LR) 30, 0 40, 5 15, 10 60, 50
Tests, HR Complete blood count, sinus 
and chest x-ray: 100%
X-ray: 10% ESR, leucocytes x-ray, 
ECG: 30%
Blood, urine, x-ray: 20%
Tests, LR As above X-ray: 10% As above Tests above: 10%
Cardiovascular
No. of visits (HR, LR) 4, 3 3, 3 5, 5 4, 3
% home visits (HR, LR) 25, 30 50, 20 70, 70 80, 70
Tests, HR Blood count, x-ray, ECG, 
echocardiography: 100%
ECG: 100% ESR, leucocytes x-ray, 
ECG, CRP: 100%
Blood, urine, ECG, 
echocardiogram: 50%
Tests, LR Id.: 90% ECG: 80%, As above Tests above: 20%
Other minor complications
No. of GP visits 3, 2 2, 2 — —
% home visits 30, 0 40, 5 — —
Data are from questionnaires completed by clinician authors, except where publication is cited.
CRP, C-reactive protein; ECG, electrocardiogram; ESR, erythrocyte sedimentation rate; GP, general physician; HR, patients at high risk of complications; ILI, inﬂuenza-like illness;
LR, patients at low risk of complications.
Table A10 Main unit costs and associated reimbursement rates, by country
Country
Perspective
Brazil France Germany Italy 
TPP Societal TPP Societal TPP Societal TPP Societal
Standard GP visit R$7.55 R$54 70% of 
€20
100% of 
€20
100% of 
€8.75
100% of 
€8.75
100% of 
€12.91
100% of 
€12.91 [76]
Home visit R$16.63 R$18.94 70% of 
€33.50
100% of 
€33.50
100% of 
€13.20
100% of 
€13.20
0% of 
€18.07*
100% of 
€18.07
Antibiotic R$0 R$2.29 65% of 
€7.55
100% of 
€7.55
€19 less 
€5 co-pay
€19 100% of 
€9.21
100% of €9.21 
[77]
Hospitalization
Pneumonia and 
inﬂuenza
R$498.11 R$3,653 80% of
€3,669*
100% of 
€3,669
100% of 
€3,671 
100% of 
€3,671
100% of 
€3,966
100% of 
€3,966
Other respiratory 
complications
R$177.59 R$1,270 80% of 
€4,362*
100% of 
€4,362
€3,327 less 
€90
€3,327 100% of 
€3,774
100% of 
€3,774
Cardiovascular and
cerebrovascular
complications
R$246.29 R$1,762 80% of 
€3,789*
100% of 
€3,789
€7,279 less 
$90
€7,279 100% of 
€3,270
100% of 
€3,270
Lost productivity, 
per workday [78]
R$0 R$85.75† 
[79]
€25.50 €216.64 €0 €226.26 €0 €164.91 
[47,76,77]
*100% reimbursement rate applies to individuals eligible for vaccination because of chronic health conditions.
Sources:
Brazil: Tabelas de Procedimentos dos Sistemas de Informações Ambulatorial e Hospitalar do Sistema Único de Saúde (SIA and SIH/SUS), 2004; DATA SUS, Sao Paulo; †IBGE,
PNAD-2002 (National Household Survey).
France: Drugs: Vidal, BIAM; Fee schedules for physician visits and tests: NGAP; Hospital costs: PMSI (data obtained from ATIH); Reimbursement rates: CNAMTS.
Germany: Drugs: Rote Liste; Fee schedules for physician visits and tests: EBM; Hospital costs: DRG database, v1.0 (2003) available at http://www.g-drg.de; Zahlenbericht, PKV;
Diagnosedaten der Krankenhauspatienten 1999, Statistiches Bundesamt 2001.
Italy: Drugs: http://www.gioﬁl.it; Tests: Prestazioni di Assistenza Specialistica Ambulatorie http://www.ministerosalute.it; Home visits: DPR270, Nomenclatore Tariffario (2000);
Hospital costs: Schede di Dimissione Ospedaliere.
GP, general physician; TPP, third-party payer.
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Table A11 Vaccine acquisition and administration costs
Brazil [15] France Germany Italy [80]
Vaccination 
setting
Public hospital or 
vaccination center, by 
nurse: 100%
Current policy: 70% routine 
visits, 20% special visits, 
10% occupational visits
New policy, high-risk: 
70% routine visits, 
20% special visits, 
10% occupational visits
New policy, low-risks: 
20% routine visits, 
70% special visits, 
10% occupation visits
Physicians perform 
all vaccinations.
Fixed item-of-service fee 
(independent of setting)
Current policy, HR: 90% in 
public sector (LHA/family 
doctor), 10% in private sector
Current policy, LR: 100% in 
private sector
New policy: 90% in public 
sector, 10% in private sector
Unit costs Vaccine: R$4.74
Vaccination by nurse:
– TPP: R$ 0.50
– Societal: R$ 3.58
Vaccine: €6.28
GP visit: €20 (routine visit: €0)
Vaccination in occupational 
setting: €2.90
Vaccine:
– Eligible person: €7.00
– Noneligible: €17.28
Physician fee: €6.50
Vaccine:
– Pharmacy: €12.77*
– Under contract: €4.98 [80]
Family doctor incentive/LHA 
administration fee: €8.00
Private doctor: €15.49
Reimbursement 100% of all costs (TPP) 
for all vaccinated 
persons
Vaccine:
– For eligible persons: 100%
– For noneligible persons: 0% 
Administration: 70% if by GP, 
0% if by nurse at occupational visit
Eligible persons: 100%
Noneligible persons: 0%
Family doctor/LHA: 100%
Private doctor: 0%
Sources:
Brazil: SIA and SIH/SUS, 2004.
France: NGAP.
Germany: Regional physicians’ associations: Wezel, Liebold. Handkommentar: BMÄ, E-GO und GOÄ, IGEL.
Italy: *http://www.gioﬁl.it/ofﬂine/SOuauett.htm (accessed January 15, 2004).
HR, patients at high risk of complications; LHA, Local Health Authority; LR, patients at low risk of complications.
Table A12 Distributions and parameters for probabilistic analyses
Model inputs France Germany Italy Brazil
Proportion of 50–64 year-olds eligible 
for vaccination reimbursement 
under existing policy
Triangular (min = 3.76%, 
mode = 4.70%, 
max = 5.64%)
Beta(α = 20, β = 180) Assumed equal to 
proportion at 
increased risk 
(see below)
Assumed equal to 
proportion at increased 
risk (see below)
Proportion of ﬂu patients aged 
50–64 years at increased risk of 
complication (HR group)
Triangular (min = 20%; 
mode = 25%; max = 30%)
Triangular (min = 20%, 
mode = 25%, 
max = 30%)
Triangular (min = 20%,
mode = 25%, 
max = 30%)
Lognormal (mean 0.3, 
SD 0.03)
Proportion of individuals seeking 
medical care for ﬂu/ILI in one 
season
Empirical distribution of 
incidences from 1985 to 
2002
French distribution 
rescaled, equating 
mean to base case 
consultation rate
French distribution 
rescaled, equating 
mean to base case 
consultation rate
French distribution 
rescaled, equating 
mean to base case 
consultation rate
Proportion of individuals with ILI 
seeking medical care
Beta(α = 178, β = 135) (4.4%/4.69%)×
Beta(178, 135).
Beta(α = 180, β = 120) Triangular
20%−40%−60%
Vaccination uptake–Existing policy Ratio eligible/noneligible 
adjusted for age: triangular 
(min = 2.5; mode = 3.22; 
max = 4)
Ratio (more than 50 : less 
than 50 years) among 
eligibles: triangular 
(min = 1; mode = 2; 
max = 3)
Overall coverage: 
Beta(α = 198, β = 646)
Ratio HR/LR: 
Beta(α = 112, 
β = 162)/
Beta(α = 176, 
β = 880)
Overall coverage:
β = 557.72)
Ratio HR/LR: 
Beta(α = 112, 
β = 162)/
Beta(α = 176, 
β = 880)
Overall coverage:
Beta(α = 161.28, 
HR: Triangular (min = 8%, 
mode = 10%, 
max = 18%)
LR: Triangular (min = 1%, 
mode = 1%, max = 4%)
Beta(α = 189, β = 606)
Probability of any hospitalization | 
ILI medically attended, 
unvaccinated
HR: Beta(α = 148, β = 1011)
LR: Beta(α = 9, β = 553)
HR:
Beta(α = 144.48; 
β = 930.38)
LR:
Beta(α = 8.47;
β = 516.94)
HR:
Beta(α = 154.75; 
β = 1219.86)
LR:
Beta(α = 9.23; 
β = 671.23)
HR: Lognormal 
(mean 0.0305, 
SD 0.0012)
LR: Lognormal 
(mean = 0.0033, 
SD = 0.0112)
Probability of death | ILI medically 
attended, unvaccinated
HR: Beta(α = 15.89; 
β = 1,638.85)
LR: Beta (α = 0.29; 
β = 1748.52)
HR: Beta(α = 16.98, 
β = 1642.76)
LR: Beta(α = 0.30, 
β = 1748.52)
HR: Beta(α = 13.69,
β = 1642.18)
LR: Beta(α = 0.26, 
β = 1735.71)
HR: Beta(α = 15.79, 
β = 1638.95)
LR: Beta(α = 0.30, 
β = 1748.52)
Number of workdays lost for 
cases seeking medical attention
Normal (Mean 4.00; 
SD 0.15)
LogNormal (3.78; 0.82) Normal (4.55; 0.71) Lognormal (mean 3.98, 
SD 1.17)
Note. As sources of data and types of evidence were country-speciﬁc for some inputs, the appropriate statistical distributions were also subject to variability.
GP, general physician; HR, patients at high risk of complications; ILI, inﬂuenza-like illness; LR, patients at low risk of complications; OR, odds ratio; TPP, third-party payer.
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Number of workdays lost for other 
cases
Prob. absence: 
Beta(α = 29, β = 36)
Mean # days | absence:
Lognormal (mean 0.68, 
SD 0.15)
Prob. absence: 
Beta(α = 29, β = 36)
Mean # days | absence:
Lognormal (Mean 
0.68, SD 0.15)
Prob. absence: 
Beta(α = 29, β = 36)
Mean # days | absence:
Lognormal (Mean 
0.68, SD 0.15)
Prob. absence: 
Beta(α = 29, β = 36)
Mean # days | absence:
Lognormal (mean 0.68, 
SD 0.15)
Vaccine effectiveness: reduction in 
risk of ILI
Normal (mean −0.34, SD 
0.11) on log(OR)
Vaccine effectiveness: Reduction in 
minor complications
Normal (mean −0.33, SD 
0.08) on log(OR)
Vaccine effectiveness: reduction in 
hospitalizations
Normal (mean −0.69, SD 
0.21) on log (OR)
Vaccine effectiveness: reduction in 
deaths
Normal (mean −1.14, SD 
0.15) on log(OR)
Vaccine administration, existing policy Occupational: Triangular 
(min = 5, mode = 8.5, 
max = 12%)
Special visit | vacc. by 
GP: Uniform (min = 10%, 
max = 35%)
— Prob. private visit, HR:
Triangular (0%−10%−
20%)
—
Vaccine administration, new policy Occupational:
Triangular (min = 5%, 
mode = 8.5%, max = 12%)
Special visit | GP, HR:
Uniform (min = 10%, 
max = 35%)
Special visit | GP, LR:
Uniform (min = 65%, 
max = 95%)
— Prob. private visit, HR:
Equal to prob. under 
existing policy (see 
above)
—
Vaccine acquisition cost (if paid by 
TPP)
— Triangular (min = €6, 
mode = €6.50, 
max = €8.50)
Triangular (min = €4.5, 
mode = €4.98, 
max = €5.5)
—
Vaccine administration cost — Triangular: (min = €5.5, 
mode = €6.50, 
max = €7.70)
Family doctor / Local 
Health Authority: 
Triangular (min = €6, 
mode = €8, 
max = €10)
By nurse:
Gamma distribution 
(Location = 0.5, 
Shape = 2.37, 
Scale = 1.30)
Hospitalization cost, societal 
perspective
— — — Gamma distribution 
(Location = 331, 
Shape = 1.84, 
Scale = 1,105.11)
Model inputs France Germany Italy Brazil
Note. As sources of data and types of evidence were country-speciﬁc for some inputs, the appropriate statistical distributions were also subject to variability.
GP, general physician; HR, patients at high risk of complications; ILI, inﬂuenza-like illness; LR, patients at low risk of complications; OR, odds ratio; TPP, third-party payer.
Table A12 continued
